# Lexicon Pharmaceuticals (LXRX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/LXRX
## Company Profile
- Ticker: LXRX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 2.35 USD
- Market cap: 839531177.0999999 USD
- Last updated: 2026-08-12
## Business Overview
### Genetically Informed Drug Discovery
Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases.
### Sotagliflozin Franchise
Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application targets adults with type 1 diabetes.
### Hypertrophic Cardiomyopathy
The SONATA-HCM study evaluates sotagliflozin in hypertrophic cardiomyopathy. Lexicon also maintains development programs in neuropathic pain, obesity and metabolic disease.
### Neuropathic-Pain and Metabolic Pipeline
Beyond sotagliflozin, Lexicon maintains discovery, preclinical and clinical candidates in neuropathic pain, obesity and other cardiometabolic disorders.
## Why The Stock Is Moving

As of Aug 12, 2026, LXRX closed down 3.29% at $2.35. No new same-company headline was identified in the current news window.

## Future Catalysts

- Completion of enrollment in SONATA-HCM around mid-2026.
- NDA resubmission for ZYNQUISTA around mid-2026.
- Topline SONATA-HCM results in the first quarter of 2027.

## Recent News
- 2026-08-06 11:30 EST — [Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provid-3ddbf00d) — Source: Lexicon Pharmaceuticals
- 2026-07-30 12:30 EST — [Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-augus-436992c6) — Source: Lexicon Pharmaceuticals
- 2026-07-27 12:30 EST — [Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-completes-enrollment-of-pivotal-phase-3-sonata-hcm-study-684930b3) — Source: Lexicon Pharmaceuticals
- 2026-06-03 12:00 EST — [Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions](https://biopharmsignal.com/news/LXRX/lexicon-to-present-data-at-the-american-diabetes-association-ada-2026-scientific-60360dc3) — Source: Lexicon Pharmaceuticals
- 2026-05-28 12:30 EST — [Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/LXRX/lexicon-pharmaceuticals-to-present-at-the-2026-jefferies-global-healthcare-confe-9895b44d) — Source: Lexicon Pharmaceuticals